Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Lawson Health Research Institute |
---|---|
Information provided by: | Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00788463 |
The purpose of this study is to determine if intranasal Beclomethasone delivered by aerosol or spray is more effective in treatment of nasal polyps.
Condition | Intervention | Phase |
---|---|---|
Nasal Polyps |
Drug: Intranasal Beclomethasone aerosol Drug: Intranasal Beclomethasone spray |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps |
Estimated Enrollment: | 60 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Aerosol: Experimental |
Drug: Intranasal Beclomethasone aerosol
Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
|
Spray: Active Comparator |
Drug: Intranasal Beclomethasone spray
Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
|
Aqueous and aerosol delivery of intranasal corticosteroids has never been directly compared previously in patients with nasal polyps and it is unknown whether one is superior.
This objective of this study is to compare the efficacy of intranasal beclomethasone by two different delivery systems, aerosol and aqueous spray in patients with nasal polyps. Primary endpoint is the difference in the overall quality of life as measured by the Rhinitis Quality of Life Questionnaire. The secondary endpoint is the change in Nasal Airflow Resistance as measured by rhinomanometry.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jorge A Mazza, MD | 519-685-8500 ext 58277 | jmazza@uwo.ca |
Canada, Ontario | |
Allergy Clinic, London Health Sciences Centre | Recruiting |
London, Ontario, Canada, N6A 4G5 |
Principal Investigator: | Jorge A Mazza, MD | University of Western Ontario, Canada |
Responsible Party: | London Health Sciences Centre ( Jorge Mazza ) |
Study ID Numbers: | R-06-542, 12801 |
Study First Received: | November 7, 2008 |
Last Updated: | November 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00788463 |
Health Authority: | Canada: Health Canada |
administration, intranasal aerosol beclomethasone QVAR corticosteroids |
nasal polyps rhinomanometry Rhinitis Quality of Life Questionnaire Quality of Life |
Pathological Conditions, Anatomical Nasal Polyps Otorhinolaryngologic Diseases Beclomethasone |
Quality of Life Polyps Rhinitis |
Anti-Inflammatory Agents Respiratory System Agents Therapeutic Uses Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Anti-Asthmatic Agents Hormones Glucocorticoids Pharmacologic Actions Nose Diseases |